Evidence map›Paper›PMID 33374986›Full record

ArticleInternational journal of molecular sciences2020

The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia.

Mitchell J Bartlett, Omar S Mabrouk, Lajos Szabò, Andrew J Flores, Kate L Parent, Jean M Bidlack, Michael L Heien, Robert T Kennedy, Robin Polt, Scott J Sherman and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Peptides for Health Benefits 2020.International journal of molecular sciences · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Mitchell J BartlettDepartment of Neurology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.ORCID 0000-0001-8280-5299
Omar S MabroukDepartment of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
Lajos SzabòDepartment of Chemistry & Biochemistry, University of Arizona, Tucson, AZ 85721, USA.
Andrew J FloresGraduate Interdisciplinary Program in Physiological Sciences, University of Arizona, Tucson, AZ 85724, USA.
Kate L ParentDepartment of Chemistry & Biochemistry, University of Arizona, Tucson, AZ 85721, USA.
Jean M BidlackDepartment of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.ORCID 0000-0002-4305-5111
Michael L HeienDepartment of Chemistry & Biochemistry, University of Arizona, Tucson, AZ 85721, USA.
Robert T KennedyDepartment of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
Robin PoltDepartment of Chemistry & Biochemistry, University of Arizona, Tucson, AZ 85721, USA.
Scott J ShermanDepartment of Neurology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.
Torsten FalkDepartment of Neurology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.ORCID 0000-0003-4999-3309
University of Arizona · USUniversity of Michigan · USUniversity of Rochester · US

Funding

POSTDOCTORAL TRAINING IN THE BIOLOGY OF DRUG ABUSET32DA007268 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TRAYNOR, JOHN R. · 1991 to 2021
$6.7M
Novel Glycosylated Delta Opioid Receptor Agonists for Chronic Inflammatory PainR43DA026653 · NIDA · BIOUSIAN BIOSYSTEMS, INC. (BBI) · PI KITSOS, CHRISTINE M · 2009 to 2009
$200k
Michael J. Fox Foundation for Parkinson's Research No numberNIDA NIH HHS R43DA026653 and R44 DA026653NIDA NIH HHS T32 DA007268
6 · The paper itself

Abstract

In previous work we evaluated an opioid glycopeptide with mixed μ/δ-opioid receptor agonism that was a congener of leu-enkephalin, MMP-2200. The glycopeptide analogue showed penetration of the blood-brain barrier (BBB) after systemic administration to rats, as well as profound central effects in models of Parkinson's disease (PD) and levodopa (L-DOPA)-induced dyskinesia (LID). In the present study, we tested the glycopeptide BBI-11008 with selective δ-opioid receptor agonism, an analogue of deltorphin, a peptide secreted from the skin of frogs (genus

Indexed as

Disease Models, AnimalAnalgesics, OpioidAnimalsCorpus StriatumDizocilpine MaleateDyskinesia, Drug-InducedGlycopeptidesLevodopaMaleMotor ActivityNeuroprotective AgentsParkinson Disease, SecondaryRats, Sprague-DawleyReceptors, Opioid, deltaAnalgesics, OpioidDizocilpine MaleateGlycopeptidesLevodopaNeuroprotective AgentsReceptors, Opioid, deltabasal gangliaL-DOPAParkinson’s disease

Identifiers

PMID33374986
PMCPMC7792611
OpenAlexW3114943711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.